Literature DB >> 15927448

Signaling to the DEAD box--regulation of DEAD-box p68 RNA helicase by protein phosphorylations.

Liuqing Yang1, Chunru Lin, Zhi-Ren Liu.   

Abstract

P68 nuclear RNA helicase is essential for normal cell growth. The protein plays a very important role in cell development and proliferation. However, the molecular mechanism by which the p68 functions in cell developmental program is not clear. We previously observed that bacterially expressed his-p68 was phosphorylated at multiple sites including serine/threonine and tyrosine [L. Yang, Z.R. Liu, Protein Expr. Purif., 35: 327]. Here we report that p68 RNA helicase is phosphorylated at tyrosine residue(s) in HeLa cells. Phosphorylation of p68 at threonine or tyrosine residues responds differently to tumor necrosis factor alpha (TNF-alpha)induced cell signal. Kinase inhibition and in vitro kinase assays demonstrate that p68 RNA helicase is a cellular target of p38 MAP kinase. Phosphorylation of p68 affects the ATPase and RNA unwinding activities of the protein. In addition, we demonstrate here that phosphorylation of p68 RNA helicase controls the function of the protein in the pre-mRNA splicing process. Interestingly, phosphorylation at different amino acid residues exhibits different regulatory effects. The data suggest that function(s) of p68 RNA helicase may be subjected to the regulation of multiple cell signal pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927448     DOI: 10.1016/j.cellsig.2005.03.008

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

Review 1.  P68 RNA helicase as a molecular target for cancer therapy.

Authors:  Ting-Yu Dai; Liu Cao; Zi-Chen Yang; Ya-Shu Li; Li Tan; Xin-Ze Ran; Chun-Meng Shi
Journal:  J Exp Clin Cancer Res       Date:  2014-08-24

Review 2.  Regulation of mammalian microRNA processing and function by cellular signaling and subcellular localization.

Authors:  Neil R Smalheiser
Journal:  Biochim Biophys Acta       Date:  2008-04-08

3.  First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.

Authors:  Anna Capasso; Stacey M Bagby; Kyrie L Dailey; Naomi Currimjee; Betelehem W Yacob; Anastasia Ionkina; Julie G Frank; Deog Joong Kim; Christina George; Young B Lee; Ely Benaim; Brian Gittleman; Sarah J Hartman; Aik Choon Tan; Jihye Kim; Todd M Pitts; S Gail Eckhardt; John J Tentler; Jennifer R Diamond
Journal:  Mol Cancer Ther       Date:  2019-09-05       Impact factor: 6.261

4.  Pisum sativum p68 DEAD-box protein is ATP-dependent RNA helicase and unique bipolar DNA helicase.

Authors:  Narendra Tuteja; Mohammed Tarique; Mst Sufara Akhter Banu; Moaz Ahmad; Renu Tuteja
Journal:  Plant Mol Biol       Date:  2014-06-08       Impact factor: 4.076

5.  Multi-talented DEAD-box proteins and potential tumor promoters: p68 RNA helicase (DDX5) and its paralog, p72 RNA helicase (DDX17).

Authors:  Ralf Janknecht
Journal:  Am J Transl Res       Date:  2010-05-05       Impact factor: 4.060

6.  Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter.

Authors:  C L Carter; C Lin; C-Y Liu; L Yang; Z-R Liu
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 7.  RNA helicases and abiotic stress.

Authors:  George W Owttrim
Journal:  Nucleic Acids Res       Date:  2006-06-21       Impact factor: 16.971

8.  P68 RNA helicase is a nucleocytoplasmic shuttling protein.

Authors:  Haizhen Wang; Xueliang Gao; Yun Huang; Jenny Yang; Zhi-Ren Liu
Journal:  Cell Res       Date:  2009-09-29       Impact factor: 25.617

9.  The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.

Authors:  Emma L Clark; Anne Coulson; Caroline Dalgliesh; Prabhakar Rajan; Samantha M Nicol; Stewart Fleming; Rakesh Heer; Luke Gaughan; Hing Y Leung; David J Elliott; Frances V Fuller-Pace; Craig N Robson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.